COMPASS研究中国亚组:利伐沙班联合阿司匹林用于稳定性心血管病二级预防
三组主要疗效终点和主要安全性终点发生率差异均无统计学意义(P>0.05),结论认为联合治疗可安全有效用于中国患者二级预防。
要点
- 中国亚组中利伐沙班联合阿司匹林组主要疗效终点1.5%/年,低于单药组但差异无统计学意义。
- 联合组主要安全性终点大出血1.0%/年,与单药组相当,差异无统计学意义。
- 联合治疗可考虑用于中国稳定性冠心病和外周动脉疾病患者的二级预防。
核心结论
- 利伐沙班与阿司匹林联用可安全有效地用于中国稳定性冠心病和外周动脉疾病患者的心血管事件二级预防。
研究设计与样本
- 患者随机分为利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次组(n=366)、利伐沙班5mg每日两次单用组(n=365)和阿司匹林100mg每日一次单用组(n=355)。
主要发现
- 主要疗效终点(心血管死亡、心肌梗死及卒中复合事件)发生率:联合组9次(1.5%/年),利伐沙班单用组21次(3.7%/年),阿司匹林单用组14次(2.5%/年)。
- 主要安全性终点(修改ISTH标准大出血)发生率:联合组6次(1.0%/年),利伐沙班单用组9次(1.6%/年),阿司匹林单用组7次(1.2%/年)。
- 临床净获益事件发生率:联合组10次(1.7%/年),利伐沙班单用组22次(3.9%/年),阿司匹林单用组15次(2.7%/年)。
- 上述终点事件三组间差异均无统计学意义(P>0.05)。
关键数值与推荐
- 主要疗效终点为心血管病死亡、心肌梗死及卒中的复合事件。
- 主要安全性终点为修改的国际血栓与止血协会(ISTH)标准大出血。
- 利伐沙班联合阿司匹林组用药方案为利伐沙班2.5mg每日两次加阿司匹林100mg每日一次。
临床怎么用
- 对于中国稳定性冠心病和外周动脉疾病患者,可考虑利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次进行心血管事件二级预防。
- 联合治疗未显著增加大出血风险,但需结合患者个体出血风险评估后使用。
局限性
- 中国亚组样本量较小,终点事件数量少,统计效能有限。
- 亚组分析结果需谨慎解读,不能替代主试验结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This analysis was performed to evaluate the efficacy and the safety of rivaroxaban-aspirin combination therapy in secondary prevention of major adverse cardiovascular events in Chinese patients enrolled in the COMPASS trial. Methods: COMPASS was a prospective, international multi-center and randomized controlled trial. From September 2014 to February 2017, 1 086 patients with stable coronary artery disease and peripheral artery diseases were recruited from 31 centers in China. Patients were randomly assigned to separately receive the therapy of rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day,) group (n=366), rivaroxaban (5 mg twice a day) alone group (n=365), and aspirin (100 mg once a day) alone group (n=355). Baseline information such as age, sex, etc. of all three groups was collected. Finally, 1 081 patients were followed up successfully, with the follow-up rate 99.5% and the average follow-up time was 19 months. The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction and stroke. The primary safety endpoint was major bleeding evaluated by modified International Society on Thrombosis and Haemostasis criteria. Results: Age of patients was (64.2±8.3) years and there were 293 male in rivaroxaban plus aspirin group. Age of patients was (63.8±9.0) years, and there were 301 male patients in rivaroxaban alone group. Age of patients was (63.6±8.8) years, and there were 282 male patients in the aspirin alone group. The incidences of primary efficacy endpoint occurred in 9 cases (1.5%) in rivaroxaban with aspirin group, 21 cases (3.7%) in rivaroxaban alone group and 14 cases (2.5%) in aspirin alone group. Meanwhile, the incidences of primary safety endpoint occurred in 6 cases (1.0%) in rivaroxaban with aspirin group, 9 cases (1.6%) in rivaroxaban alone group and 7 cases (1.2%) in aspirin alone group. The net clinical benefit events were 10 cases (1.7%) in rivaroxaban with aspirin group, 22 cases (3.9%) in rivaroxaban alone group and 15 cases (2.7%) in aspirin alone group (P>0.5%). Conclusions: The combination of rivaroxaban with aspirin can be safe and effectively used for the secondary prevention in Chinese patients with stable coronary artery disease and peripheral artery diseases. 目的: 基于“采用抗凝策略人群中的心血管结局(COMPASS)”的中国亚组数据,分析利伐沙班与阿司匹林联用对稳定性心血管疾病患者心血管事件二级预防的疗效与安全性。 方法: COMPASS研究是一项前瞻性、国际多中心、随机、平行组设计的临床试验。本研究选取其中2014年9月至2017年2月中国31家医学中心的稳定性心血管病患者(诊断为稳定性冠心病、外周动脉疾病或两者同时存在)进行亚组分析,采用随机数表法分为利伐沙班与阿司匹林联用组、利伐沙班单用组及阿司匹林单用组。收集3组的年龄、性别等基线临床资料。患者于随机分配后第1、6个月以及此后每隔6个月于门诊或电话中接受随访。观察的主要疗效终点是心血管病死亡、心肌梗死及卒中的复合事件,主要安全性终点为修改的国际血栓与止血协会标准大出血,评价临床净获益及其他不良事件发生情况。采用Kaplan-Meier生存曲线估算终点事件的年化发生率,并采用分层Cox比例风险回归模型分析比较3组终点事件及临床净获益事件风险的差异。 结果: COMPASS研究中国亚组共纳入1 086例稳定性心血管疾病患者,其中利伐沙班与阿司匹林联用组366例,年龄(64.2±8.3)岁,男性293例(80.1%);利伐沙班单用组365例,年龄(63.8±9.0)岁,男性301例(82.5%);阿司匹林单用组355例,年龄(63.6±8.8)岁,男性282例(79.4%)。最终共1 081例患者完成随访,随访率为99.5%,中位随访时间为575(413,673)d。利伐沙班与阿司匹林联用组主要疗效终点事件发生9次(1.5%/年),利伐沙班单用组发生21次(3.7%/年),阿司匹林单用组发生14次(2.5%/年);主要安全性终点3组分别为6次(1.0%/年)、9次(1.6%/年)及7次(1.2%/年);临床净获益事件3组分别为10次(1.7%/年)、22次(3.9%/年)、15次(2.7%/年),差异均无统计学意义(P>0.05)。其他不良事件在中国亚组中发生较少。 结论: 利伐沙班与阿司匹林联用以可安全有效地用于中国稳定性冠心病和外周动脉疾病患者的心血管事件二级预防。.
引用
- Liang Y, Gong ZB, Lou KJ, et al. [Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34530594. doi:10.3760/cma.j.cn112148-20210319-00247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。